R. Megna Michael's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 15,211 Class A Ordinary Share done at an average price of $28.7 . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 28.75 per share. | 03 Jun 2025 | 15,211 | 32,546 (0%) | 0% | 28.7 | 437,316 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 03 Jun 2025 | 15,211 | 47,757 (0%) | 0% | 15.5 | 235,771 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 15,211 | 791 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 26.69 per share. | 07 May 2025 | 17,647 | 32,546 (0%) | 0% | 26.7 | 470,998 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 14,420 | 17,040 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 07 May 2025 | 14,420 | 50,193 (0%) | 0% | 12.0 | 172,607 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 2,998 | 16,002 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.50 per share. | 07 May 2025 | 2,998 | 35,773 (0%) | 0% | 15.5 | 46,469 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 07 May 2025 | 229 | 32,775 (0%) | 0% | 8.8 | 2,022 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 229 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,456 | 5,456 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,285 | 5,285 | - | - | Performance Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 3,433 | 3,433 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 3,270 | 3,270 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 3,933 | 34,212 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 3,933 | 3,932 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 1,666 | 32,546 (0%) | 0% | 20.3 | 33,786 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 21,150 | 21,150 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 10,575 | 10,575 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 2,557 | 30,000 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 2,557 | 5,115 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 2,363 | 7,087 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 2,363 | 32,363 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 1,083 | 31,280 (0%) | 0% | 21.8 | 23,577 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 1,001 | 30,279 (0%) | 0% | 21.8 | 21,792 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 774 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 774 | 27,771 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 16.00 per share. | 16 Mar 2025 | 469 | 26,997 (0%) | 0% | 16 | 7,504 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 328 | 27,443 (0%) | 0% | 22.6 | 7,416 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 12 Mar 2025 | 9,051 | 35,579 (0%) | 0% | 11.1 | 100,466 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 9,051 | 13,763 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 22.45 per share. | 12 Mar 2025 | 9,051 | 26,528 (0%) | 0% | 22.5 | 203,195 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 22.45 per share. | 27 Nov 2024 | 8,637 | 26,528 (0%) | 0% | 22.5 | 193,901 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 8,637 | 22,823 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 27 Nov 2024 | 8,637 | 35,165 (0%) | 0% | 11.1 | 95,871 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 9 | 22,814 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 27 Nov 2024 | 9 | 26,528 (0%) | 0% | 22.4 | 202 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.11 per share. | 27 Nov 2024 | 9 | 26,537 (0%) | 0% | 11.1 | 100 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 175 | 26,610 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 175 | 175 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.48 per share. | 04 Oct 2024 | 82 | 26,528 (0%) | 0% | 24.5 | 2,007 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 18,900 | 18,900 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 9,450 | 9,450 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 6,490 | 28,744 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 3,932 | 7,865 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 2,755 | 25,989 (0%) | 0% | 26.7 | 73,669 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,558 | 7,672 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 775 | 774 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 775 | 26,764 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 15.65 per share. | 15 Jul 2024 | 480 | 22,254 (0%) | 0% | 15.7 | 7,512 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 329 | 26,435 (0%) | 0% | 26.7 | 8,797 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 18,900 | 18,900 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 9,450 | 17,122 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 3,932 | 22,994 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 3,932 | 13,190 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 1,666 | 21,328 (0%) | 0% | 17.9 | 29,821 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 2,558 | 7,672 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 2,558 | 20,146 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.70 per share. | 01 Apr 2024 | 1,084 | 19,062 (0%) | 0% | 19.7 | 21,355 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 21.45 per share. | 28 Feb 2024 | 9,659 | 17,588 (0%) | 0% | 21.5 | 207,186 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 28 Feb 2024 | 5,645 | 23,233 (0%) | 0% | 8.8 | 49,845 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,645 | 229 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 28 Feb 2024 | 5,126 | 22,714 (0%) | 0% | 8.8 | 45,263 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 21.79 per share. | 28 Feb 2024 | 5,126 | 17,588 (0%) | 0% | 21.8 | 111,696 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 5,126 | 5,874 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 4,014 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 28 Feb 2024 | 4,014 | 27,247 (0%) | 0% | 13.9 | 55,714 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 12.35 per share. | 28 Feb 2024 | 583 | 17,588 (0%) | 0% | 12.3 | 7,200 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael Megna R. | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 16,670 | 4,014 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 19.17 per share. | 02 Jan 2024 | 16,670 | 17,005 (0%) | 0% | 19.2 | 319,564 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | R. Megna Michael | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 02 Jan 2024 | 16,670 | 33,675 (0%) | 0% | 13.9 | 231,380 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Megna R. Michael | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 9,316 | 20,684 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Megna R. Michael | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 19 Dec 2023 | 9,316 | 26,321 (0%) | 0% | 13.9 | 129,306 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | R. Michael Megna | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 19.13 per share. | 19 Dec 2023 | 9,316 | 17,005 (0%) | 0% | 19.1 | 178,215 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 3,933 | 14,132 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 3,933 | 11,797 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 10 Apr 2023 | 1,155 | 12,977 (0%) | 0% | 10.7 | 12,370 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 20,459 | 20,459 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 10,230 | 10,230 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,163 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,163 | 10,834 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 774 | 1,549 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 774 | 8,892 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 15 Jan 2023 | 704 | 8,118 (0%) | 0% | 9.6 | 6,730 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.12 per share. | 15 Jan 2023 | 635 | 10,199 (0%) | 0% | 11.1 | 7,061 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.46 per share. | 15 Jan 2023 | 221 | 8,671 (0%) | 0% | 11.5 | 2,533 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2022 | 175 | 525 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2022 | 175 | 7,466 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.23 per share. | 04 Oct 2022 | 52 | 7,414 (0%) | 0% | 14.2 | 740 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 31,460 | 31,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 15,730 | 15,730 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 775 | 7,519 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 775 | 2,323 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 01 Sep 2022 | 703 | 6,744 (0%) | 0% | 9.6 | 6,721 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.44 per share. | 01 Sep 2022 | 228 | 7,291 (0%) | 0% | 11.4 | 2,608 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 31,460 | 31,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 15,730 | 15,730 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 3,231 | 7,161 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 3,231 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | CHIEF ACCOUNTING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.98 per share. | 21 Mar 2022 | 1,120 | 6,041 (0%) | 0% | 11.0 | 12,298 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Michael R. Megna | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 700 | 700 | - | - | Restricted Share Units |